Media stories about Trevena (NASDAQ:TRVN) have trended somewhat positive recently, according to AlphaOne. The research group, a subsidiary of Accern, identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. AlphaOne ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Trevena earned a media sentiment score of 0.08 on AlphaOne’s scale. AlphaOne also assigned news headlines about the biopharmaceutical company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted AlphaOne Sentiment Analysis’s scoring:
- Trevena Inc (TRVN) Downgraded by ValuEngine (americanbankingnews.com)
- Trevena to Present at Investor Conferences in June (finance.yahoo.com)
- Shares Seesawing on Volume: Trevena Inc (TRVN) – Concord Register (concordregister.com)
- More heavy lifting for Trevena Inc. (NASDAQ:TRVN)? – FinancialsTrend (financialstrend.com)
- Trevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (finance.yahoo.com)
Several research firms have recently weighed in on TRVN. ValuEngine cut shares of Trevena from a “sell” rating to a “strong sell” rating in a research note on Friday. Needham & Company LLC increased their price objective on shares of Trevena from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, May 15th. HC Wainwright reaffirmed a “buy” rating on shares of Trevena in a research report on Monday, May 8th. Roth Capital set a $9.00 price objective on shares of Trevena and gave the stock a “buy” rating in a research report on Saturday, May 6th. Finally, Oppenheimer Holdings Inc. set a $10.00 price objective on shares of Trevena and gave the stock a “buy” rating in a research report on Thursday, May 4th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating to the stock. Trevena has an average rating of “Buy” and an average target price of $11.73.
Trevena (NASDAQ:TRVN) traded up 2.00% during trading on Friday, hitting $2.55. 552,254 shares of the company were exchanged. The company’s market capitalization is $148.67 million. The company has a 50-day moving average of $3.12 and a 200-day moving average of $4.82. Trevena has a 12 month low of $2.15 and a 12 month high of $8.00.
Trevena (NASDAQ:TRVN) last issued its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.19. Trevena had a negative net margin of 841.00% and a negative return on equity of 66.50%. Analysts forecast that Trevena will post ($1.51) EPS for the current year.
Trevena Company Profile
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Receive News & Ratings for Trevena Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc and related companies with MarketBeat.com's FREE daily email newsletter.